CN118591556A - SIRPγ抗体及其用途 - Google Patents

SIRPγ抗体及其用途 Download PDF

Info

Publication number
CN118591556A
CN118591556A CN202280087148.6A CN202280087148A CN118591556A CN 118591556 A CN118591556 A CN 118591556A CN 202280087148 A CN202280087148 A CN 202280087148A CN 118591556 A CN118591556 A CN 118591556A
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
acid sequence
sirpγ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280087148.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·潘尼克
A·D·罗森塔尔
E·L·罗斯
A·G·Y·蔡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elecla Therapeutics
Original Assignee
Elecla Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elecla Therapeutics filed Critical Elecla Therapeutics
Publication of CN118591556A publication Critical patent/CN118591556A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280087148.6A 2021-11-10 2022-11-10 SIRPγ抗体及其用途 Pending CN118591556A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163277966P 2021-11-10 2021-11-10
US63/277,966 2021-11-10
PCT/US2022/079668 WO2023086906A2 (en) 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN118591556A true CN118591556A (zh) 2024-09-03

Family

ID=84488592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280087148.6A Pending CN118591556A (zh) 2021-11-10 2022-11-10 SIRPγ抗体及其用途

Country Status (11)

Country Link
US (1) US20240400677A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429768A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024543385A (cg-RX-API-DMAC7.html)
KR (1) KR20240099454A (cg-RX-API-DMAC7.html)
CN (1) CN118591556A (cg-RX-API-DMAC7.html)
AU (1) AU2022386652A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237787A1 (cg-RX-API-DMAC7.html)
IL (1) IL312776A (cg-RX-API-DMAC7.html)
MX (1) MX2024005740A (cg-RX-API-DMAC7.html)
TW (1) TW202334224A (cg-RX-API-DMAC7.html)
WO (1) WO2023086906A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
TW202547858A (zh) * 2024-04-22 2025-12-16 美商電子療法股份有限公司 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
MX2021015937A (es) * 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.

Also Published As

Publication number Publication date
WO2023086906A3 (en) 2023-06-22
AU2022386652A1 (en) 2024-06-06
IL312776A (en) 2024-07-01
KR20240099454A (ko) 2024-06-28
WO2023086906A2 (en) 2023-05-19
MX2024005740A (es) 2024-08-06
US20240400677A1 (en) 2024-12-05
TW202334224A (zh) 2023-09-01
JP2024543385A (ja) 2024-11-21
CA3237787A1 (en) 2023-05-19
EP4429768A2 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
KR102422411B1 (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
KR102052400B1 (ko) 담낭암의 치료 및/또는 예방용 의약 조성물
KR102094022B1 (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2b와의 융합체
AU2022298850B2 (en) Anti-ccr8 antibodies and uses thereof
CN114007699A (zh) 拮抗剂抗cd7抗体
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
KR20220129030A (ko) 항-Gal3 항체 및 사용 방법
US20240400677A1 (en) Sirp gamma antibodies and uses thereof
JP2016011306A (ja) ヒト化axl抗体
JP2016516798A (ja) ヒトのcsf−1rに対する抗体及びtlr9アゴニストの併用療法
RS65804B1 (sr) Humanizovana anti-il-1r3 antitela
CN111183157A (zh) Cd138抗体分子及其用途
JP7843824B2 (ja) 抗体および使用方法
CN115768795A (zh) SIRPα及SIRPβ1抗体及其用途
KR20240152879A (ko) 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
KR102760955B1 (ko) Gucy2c 결합 폴리펩타이드 및 그의 용도
JP7430137B2 (ja) 抗体および使用方法
CA3207703A1 (en) Anti-s100a4 humanized antibodies, uses and methods
JP2022550364A (ja) 新規抗pd-l1/抗lag-3二重特異性抗体およびその使用
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
CN114573703A (zh) 一种t细胞衔接器治疗剂的开发和应用
KR20240055852A (ko) D3-결합 분자 및 이의 용도
KR20220053000A (ko) Cr2 결합 단백질 및 의료 요법에서의 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination